Published in World J Clin Oncol on December 10, 2014
HPV prophylactic vaccination in males improves the clearance of semen infection. EBioMedicine (2015) 0.86
Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines (2016) 0.79
Human Papilloma Virus Infection Does Not Predict Response to Interferon Therapy in Ocular Surface Squamous Neoplasia. Ophthalmology (2015) 0.77
HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities. BMC Infect Dis (2017) 0.77
Cefradine blocks solar-ultraviolet induced skin inflammation through direct inhibition of T-LAK cell-originated protein kinase. Oncotarget (2016) 0.76
Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines. PLoS One (2016) 0.75
Identification of several high-risk HPV inhibitors and drug targets with a novel high-throughput screening assay. PLoS Pathog (2017) 0.75
Inhibition of antiviral drug cidofovir on proliferation of human papillomavirus-infected cervical cancer cells. Exp Ther Med (2016) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA (2002) 15.59
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 13.10
Human papillomavirus and cervical cancer. Lancet (2007) 12.47
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 11.15
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer (2007) 10.29
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
Chapter 2: The burden of HPV-related cancers. Vaccine (2006) 7.70
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer (2006) 6.59
2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol (2007) 6.25
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79
Worldwide burden of cervical cancer in 2008. Ann Oncol (2011) 5.66
Global burden of human papillomavirus and related diseases. Vaccine (2012) 5.48
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer (2007) 3.99
Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine (2006) 3.51
Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev (2005) 3.40
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis (2000) 3.36
Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res (2006) 3.17
Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol (2005) 2.77
The biology and life-cycle of human papillomaviruses. Vaccine (2012) 2.53
CD8(+) T cells: foot soldiers of the immune system. Immunity (2011) 2.45
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer (2007) 2.37
Immune responses to human papillomavirus. Vaccine (2006) 2.37
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 2.31
Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res (2005) 2.21
Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol (1999) 2.12
Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res (2008) 2.06
Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis (2004) 2.06
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Epidermodysplasia verruciformis as a model in studies on the role of papovaviruses in oncogenesis. Cancer Res (1972) 1.91
Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol (1999) 1.90
Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res (2004) 1.90
Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res (2001) 1.89
Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer (2010) 1.89
Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol (2002) 1.88
European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect (2000) 1.80
A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res (2009) 1.79
TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol (2007) 1.70
Clinical applications of DNA vaccines: current progress. Clin Infect Dis (2011) 1.65
Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch Biochem Biophys (2000) 1.63
Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds? Ann Med (2011) 1.54
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A (2007) 1.53
The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice. J Clin Invest (2012) 1.52
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51
Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nat Rev Drug Discov (2013) 1.50
Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother (1998) 1.47
Therapy for genital human papillomavirus-related disease. J Clin Virol (2005) 1.45
Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer (1999) 1.44
The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene (1999) 1.44
Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res (2003) 1.40
Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J Virol (2002) 1.32
Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol (1998) 1.32
Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. Proc Natl Acad Sci U S A (2006) 1.31
CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer (2007) 1.31
A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol (2005) 1.31
The papillomavirus E2 proteins. Virology (2013) 1.30
New technologies and procedures for cervical cancer screening. Vaccine (2012) 1.29
Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine (2008) 1.28
Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One (2011) 1.26
Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res (2003) 1.24
The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin Cancer Biol (2006) 1.23
ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2004) 1.22
HPV innate immunity. Front Biosci (2002) 1.21
Imiquimod: modes of action. Br J Dermatol (2003) 1.20
In situ hybridization analysis of human papillomavirus DNA segregation patterns in lesions of the female genital tract. Gynecol Oncol (1990) 1.19
Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev (2000) 1.19
Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18
Th1 cytokine patterns in cervical human papillomavirus infection. Clin Diagn Lab Immunol (1999) 1.18
Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol (2007) 1.18
Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine (2012) 1.17
Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine (2008) 1.16
Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther (2004) 1.16
Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. Gynecol Oncol (2012) 1.15
Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res (2003) 1.12
Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine (2004) 1.12
Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis (2006) 1.11
Therapy of human papillomavirus-related disease. Vaccine (2012) 1.11
Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer (2006) 1.11
Immune responses to human papilloma viruses. Indian J Med Res (2009) 1.10
Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol (2003) 1.10
Papillomavirus infections and human genital cancer. Gynecol Oncol (1981) 1.10
The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis (2011) 1.10
Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med Chem (2006) 1.09
Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother (2000) 1.09
Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol (2011) 1.09
Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther (2006) 1.08
Host immune responses to cervical cancer. Curr Opin Obstet Gynecol (2009) 1.06
Clinical development of Modified Vaccinia virus Ankara vaccines. Vaccine (2013) 1.06
Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses. Cancer Res (2004) 1.05
Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer (2007) 1.04
Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol (2007) 1.03
A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol (2007) 1.02
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med (2013) 1.02
Tumor-specific regulatory T cells in cancer patients. Hum Immunol (2008) 1.01
Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells. J Immunol (2001) 1.01